| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3329678 | Critical Reviews in Oncology/Hematology | 2009 | 10 Pages |
Abstract
Taxanes are very effective agents in several types of cancer. However, their activity is counterbalanced by side effects that could represent a limitation of their use in older cancer patients. This review aims at evaluating whether or not there are data supporting a tailored use of standard taxanes i.e. docetaxel and paclitaxel in elderly patients with the aim to increase their therapeutic index. In addition, recent data on the role of nanoparticle albumine-bound paclitaxel in breast cancer are discussed in this paper.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Laura Biganzoli, Sara Licitra, Erica Moretti, Marta Pestrin, Elena Zafarana, Angelo Di Leo,